IFF first quarter
This article was originally published in The Rose Sheet
Executive SummaryNorth American functional fragrance sales rose 20% in Q1 based on "new wins," but 20% decline in fine fragrance revenues led to flat fragrance performance overall for the region, excluding businesses divested in 2001, Chief Financial Officer Doug Wetmore states during April 25 financial report. European fragrance sales declined 1% in dollar terms, pulled down by high single-digit decrease in fine fragrances. Worldwide fragrance sales off 3% during quarter on pro forma basis, excluding businesses sold in late 2001 and reflecting new accounting rules for goodwill and intangibles, according to firm's April 25 1sales and earnings release. Consolidated sales of $445.8 mil. for Q1 were down 3.9% on pro forma basis. Net earnings doubled to $41.9 mil., up from $20.3 mil. in previous-year period...
You may also be interested in...
AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.
US FDA officials tell industry that implementing a quality metrics program is an agency priority and that a rejiggered program will incorporate various elements of other quality metrics initiatives being piloted by the agency, industry and academia.
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.